Oncology News | pharmaphorum

News

Arcus and Gilead drop A2R drug for prostate cancer

Arcus and Gilead Sciences have decided not to continue the development of their A2 receptor antagonist etrumadenant in castration-resistant prostate cancer (CRPC) after an

News

Astellas adds to cell therapy drive with Poseida deal

Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.

News

AZ and BMS resolve checkpoint inhibitor patent disputes

AstraZeneca has said that a trio of lawsuits filed by Bristol-Myers Squibb and Ono Pharma alleging patent infringement with its checkpoint inhibitor drugs Imjudo and Imfin

News

AI shows its value in mammography screening

A study has shown that artificial intelligence can be safely used to support mammography to spot breast cancers and may spot more tumours than the current standard approac

News

EQRx's low-price drugs mission ends with Revolution buy

EQRx's pledge to disrupt the pharma pricing system started with a clarion call in 2020 but ended with a whimper today with an agreement to be taken over by Revolution Medi

News

Boehringer moves liposarcoma drug into pivotal trial

Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with l

Arcus and Gilead drop A2R drug for prostate cancer

Astellas adds to cell therapy drive with Poseida deal

AZ and BMS resolve checkpoint inhibitor patent disputes

AI shows its value in mammography screening

EQRx's low-price drugs mission ends with Revolution buy

Boehringer moves liposarcoma drug into pivotal trial

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks